PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact


Search


PDF Archive search engine
Last database update: 18 September at 12:34 - Around 220000 files indexed.

Show results per page

Results for «lenalidomide»:


Total: 7 results - 0.026 seconds

ASH 2011.Jessica McDaniel 100%

CD28null T cell Expansion Impairs Lenalidomide Immunomodulatory Function in Myelodysplastic Syndrome Jessica McDaniel1,2, JianXiang Zou2, Alan F.

https://www.pdf-archive.com/2011/12/06/ash-2011-jessica-mcdaniel/

06/12/2011 www.pdf-archive.com

ASH 2011 Bystander vaccine poster 81%

ENHANCED IMMUNOLOGICAL RESPONSES FOLLOWING K562/GM-CSF/CD40L VACCINE PLUS LENALIDOMIDE IN HIGH-RISK MYELODYSPLASTIC SYNDROME John Powers, Eric Padron, Jason Dubovsky, Emmanuel Berchmans, Tyler Farnum, Fanqi Bai, Eva Sahakian, Jamil Ahmed, Rami S.

https://www.pdf-archive.com/2011/12/08/ash-2011-bystander-vaccine-poster/

08/12/2011 www.pdf-archive.com

dr richard isaacs md big1746 67%

Compare that with a later iteration of the same drug - Lenalidomide - which in 2014 carried a list price of $8353.

https://www.pdf-archive.com/2015/11/05/dr-richard-isaacs-md-big1746/

05/11/2015 www.pdf-archive.com

US-POM dosing guide 2016 56%

POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

https://www.pdf-archive.com/2016/11/07/us-pom-dosing-guide-2016/

07/11/2016 www.pdf-archive.com

programma 47%

Continuous lenalidomide treatment for newly diagnosed multiple myeloma (NEJM 2012;

https://www.pdf-archive.com/2018/02/09/programma/

09/02/2018 www.pdf-archive.com

Blood Cancer Drugs Market 45%

Global Blood Cancer Drugs Market Analysis, by Product 2017 – 2023 4.1 Rituaxan/Mabthera (Rituximab) 4.2 Gleevac/Glivec (Imatinib) 4.3 Revlimid (Lenalidomide) 4.4 Velcade (Bortezomib) 4.5 Tasigna (Nilotinib) 4.6 Pomalyst (Pomalidomide) 4.7 Vidaza (Azacitidine) 4.8 Kyprolis (Carfilzomib) 4.9 Adcetris (Brentuximab Vedotin) Infinium Global Research

https://www.pdf-archive.com/2018/05/04/blood-cancer-drugs-market/

04/05/2018 www.pdf-archive.com

Riches CV March 2016 32%

Maintenance Lenalidomide Post Allogeneic Hematopoietics Cell Transplantation for High-risk Multiple Myeloma.

https://www.pdf-archive.com/2016/11/15/riches-cv-march-2016/

15/11/2016 www.pdf-archive.com